Cargando…
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study
BACKGROUND AND AIM: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucose-lowering drugs that increase urinary glucose excretion have been shown to reduce CV events in patients with type 2 diabetes (T2D). Furthermore, several studies have demonstrated that treatment with SGLT2 inhibitors affect...
Autores principales: | Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Möllmann, Julia, Wied, Stephanie, Hohl, Mathias, Marx, Nikolaus, Lehrke, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857445/ https://www.ncbi.nlm.nih.gov/pubmed/35242892 http://dx.doi.org/10.1016/j.bonr.2022.101175 |
Ejemplares similares
-
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
por: Thiele, Kirsten, et al.
Publicado: (2022) -
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
por: Rau, Matthias, et al.
Publicado: (2021) -
The acute inflammatory response to copper(II)-doped biphasic calcium phosphates
por: Thoraval, L., et al.
Publicado: (2023) -
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(−/−) mice by blocking monocyte/macrophage activation
por: Kahles, Florian, et al.
Publicado: (2018) -
Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
por: Chung, Cheng-Chih, et al.
Publicado: (2023)